

13 OCTOBER 2017, 92th YEAR / 13 OCTOBRE 2017, 92^e ANNÉE

No 41 2017 92

<http://www.who.int/wer>

Executive summary of the 6th meeting of the WHO Expert Working Group of the Global Influenza Surveillance and Response System (GISRS) for Surveillance of Antiviral Susceptibility

10–11 April 2017.

Overview of activities undertaken by the AVWG since the 5th meeting in 2015

and published the “Global update on the susceptibility

¹ and the “Global update on the suscep-

² in *Antiviral Research* in 2016 and

³ of

was updated in October 2016.

Review of NA inhibitor susceptibility of circulating viruses

Review of WHO External Quality Assurance Project (EQAP) panels


panel was further expanded to include both phenotypic
and genotyping assays for evaluating antiviral suscep-

scored based on ability to correctly interpret and report
results obtained.

N. meningitidis serogroup C
Streptococcus pneumoniae.

Table 1 Recommendations of WHO expert group on serogroup C meningococcal meningitis epidemics in the African meningitis belt: 2015 and 2017

Tableau 1 Recommandations du groupe d'experts de l'OMS relatives aux épidémies de méningite à méningocoque du sérotype C dans la ceinture méningitique africaine: 2015 et 2017

Recommendations of the WHO expert group – Recommandations du groupe d'experts de l'OMS	
2015	2017
<p>Risk assessment – Évaluation des risques</p> 	

Preparedness – Préparation

-
-
areas) would be useful and could be used to advocate

WHO verification guidelines for onchocerciasis

needed before *O. volvulus*

¹ When all onchocerciasis foci in

Figure 1 Ivermectin treatment history in the north-east focus of the Bolivarian Republic of Venezuela, 2001–2012
Figure 1 Historique des traitements par l'ivermectine dans le foyer du nord-est de la République bolivarienne du Venezuela

Table 1

Table 1 **North-east focus of the Bolivarian Republic of Venezuela (fact sheet)**
 Tableau 1 **Foyer du nord-est en République bolivarienne du Venezuela (aide-mémoire)**

Population at risk – Population à risque

Main vector – Principal vecteur

Onchocerciasis transmission status – Situation de la transmission de l'onchocercose

MDA years – Période d'AMM

2 times-per-year treatment rounds since 2001 – Tournées semestrielles de traitement depuis 2001

4 times-per-year treatment rounds (in selected areas) since 2010 – Tournées trimestrielles de traitement (dans certaines zones) depuis 2010

Treatment approaches – Schémas thérapeutiques

Hyper-endemic communities – Communautés en zone de forte endémie

Meso-endemic communities – Communautés en zone d'endémie modérée

Hypo-endemic communities – Communautés en zone de faible endémie

Sentinel communities – Communautés sentinelles

§ÉT] é ^] TəSTə'actə] SÉ\ Xı

Extra-sentinel communities – Communautés extra-sentinelles

' é" é] é ^] TəSTə'actə] SÉ\ Xıə'əšé
T] é ^] TəSı] SÉ\ Xıə ^SÉəTı

2012 parasitology – Parasitologie 2012

< Xıəç[PəRTə] dəZ])žİ" * é é: Xıəç[PəİbəSP] bəPé TPd)žİfl" *

2012 ophthalmology – Ophtalmologie 2012

< Xıəç[PəRTə] d'VTP] d'Xıə'ə'VPA Qıəš< W2ı)žİ! " é é: Xıəç[PəİbəSP] bə

< Xıəç[PəRTə] d'ə] TPé< Wı)žİ! " é é: Xıəç[PəİbəSP] bəPə'ə] ÉT)žİfl" *

2012 serology in children (Ov16 IgG4 Antibodies by ELISA) – Sérologie chez l'enfant 2012 (anticorps IgG4 Ov16 par ELISA)

2012 entomology – Entomologie 2012

ə'ə'ə' \$" é əZ'əZ'flı

bPı'ı]] Xıə)žİə'ə'ə' \$" é əZ'ə flı

Post-treatment surveillance (PTS) – Surveillance post-thérapeutique (PTS)

2015-2017 Post PTS entomology – Entomologie post-PTS 2015-2017

žİfl" ! žZİə'ə'ə' \$" é əZ'flı!) žİfl" ! žZİ!

bX] dPı'ı]] Xıə)žİfl &ə'ə'ə' \$" é əZ'ə" ə flı

29R"] çST] RTə] d'əP] é< 30)ə PəbəSəVəFS\ XıəPıX] *ə'CBé 'bcaıTPä T] ədäeTı[P] RTé əZ)ə] d'əP] [TəSTəR"] çP] RT'ə< <)FS\ XıəPıX] é Pəb'əTəSTä. ÉŠXıPä T] d'ə'CB] d'äeTı[P] RTé 'bcaı

there was PCR positivity for *O. volvulus* detected in

coordination était préoccupé par des résultats de PCR positifs pour *O. volvulus*

certainly be such a case. ■

le Brésil. ■

Comment accéder au REH sur Internet?

STé] PeXPcX] é F F fê R^]] TRçTi æ^dbé Àé [Pé _PVTé SyPRRITX

0eX] 0] edT] i P6

http://www.who.int/csr/disease/avian_influenza/en/

<http://www.who.int/buruli/en/>

http://www.who.int/child_adolescent_health/en/

<http://www.who.int/cholera/en/>

<http://www.who.int/csr/delibepidemics/informationresources/en/>

<http://apps.who.int/globalatlas/>

<http://www.who.int/csr/en/>

http://www.who.int/topics/infectious_diseases/en/

http://www.who.int/topics/infectious_diseases/factsheets/en/

<http://www.filaria.org>

<http://gamapserver.who.int/mapLibrary/>

<http://apps.who.int/globalatlas/>

<http://www.who.int/csr/outbreaknetwork/en/>

<http://www.who.int/topics/en>

http://www.who.int/trypanosomiasis_african/en/

8 edT] i P6

<http://www.who.int/csr/disease/influenza/en/>

8 edT] i P] Td ^az5d=Taé

<http://who.int/flunet>

<http://www.who.int/ihr/en/>

<http://www.who.int/ith/en/>

<http://www.who.int/leishmaniasis/en/>

<http://www.who.int/lep/en/>

;h_VPRe]Pa]P6

http://www.who.int/lymphatic_filariaisis/en/

<http://www.who.int/malaria/en>

http://www.who.int/neglected_diseases/en/